Pharmacokinetic Studies of Factor VIII in Chinese Boys with Severe Hemophilia A: A Single-Center Study

被引:9
|
作者
Chen ZhenPing [1 ]
Li PeiJing [1 ]
Li Gang [1 ]
Tang Ling [1 ]
Zhen YingZi [1 ]
Wu XinYi [1 ]
Cheng XiaoLing [1 ]
Hung Luke Koon [2 ]
Blanchette Victor S [3 ]
Poon ManChiu [4 ]
Ding QiuLan [5 ]
Wu RunHui
机构
[1] Hematology Oncology Center, Beijing Children’s Hospital, Capital Medical University, Beijing Key Laboratory of Pediatric Hematology Oncology, National Key Discipline of Pediatrics, Ministry of Education, Beijing 100045, China
[2] Department of Medicine, Pediatrics and Oncology, and Southern Alberta Rare Blood and Bleeding Disorders Comprehensive Care Program, University of Calgary, Foothills Hospital and Calgary Health Region, Calgary, Alberta, T2N2T9, Canada
[3] Department of Pediatrics and Laboratory Medicine, and Hemophilia Clinic, Children’s Hospital of Eastern Ontario and University of Ottawa, Ottawa, Ontario, K1H 8L1, Canada
[4] Department of Laboratory Medicine, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai 200025, China
[5] Department of Pediatrics and Child Health Evaluative Sciences, Division of Hematology/Oncology, Research Institute, Hospital for Sick Children, University of Toronto, Toronto, Ontario, M5G 1X8, Canada
关键词
Boys; Factor VIII; Hemophilia A; Pharmacokinetics;
D O I
暂无
中图分类号
R554.1 [];
学科分类号
摘要
Background: Although much attention has been paid to the pharmacokinetics (PKs) of different factor VIII (FVIII) concentrates in persons with hemophilia A (HA), limited information is available in young boys with severe HA. In this study, we aimed to assess the PK parameters of FVIII products in boys with severe HA in China.Methods: A total of 36 boys (plasma-derived [pd]-FVIII,n = 15; recombinant [r] FVIII,n = 21) were enrolled between January 2015 and May 2016 in Beijing Children’s Hospital. PK characteristics of FVIII products were studied according to a reduced 4-sampling time point design (1 h, 9 h, 24 h, and 48 h postinfusion).Results: The mean FVIII half-life (t1/2) was 10.99 ± 3 .45 h (range 5.52- 20.02 h), the meanin vivo recovery (IVR) was 2.01 ± 0.42 IU/dl per IU/kg (range 1.24–3.02 IU/dl per IU/kg) and mean clearance (CL) of FVIII is 4.34 ± 1.58 ml·kg?1·h?1 (range 2.29–7.90 ml·kg?1·h?1). We also analyzed the influence of several parameters that potentially modulate FVIII PK. The age was closely associated with FVIII half-life (R2 = 0.32,P< 0.01). The t1/2 of FVIII increased by 0.59 h per year. Besides age, von Willebrand factor antigen (VWF:Ag) also was associated with FVIII half-life (R2 = 0.52,P< 0.01). Patients with blood Group O had a shorter FVIII half-life than patients with non-O blood group (9.40 ± 0.68 h vs. 12.3 ± 0.79 h,t = 2.70,P= 0.01). The FVIII IVR correlated with age (R2 = 0.21,P< 0.01) and VWF:Ag level (R2 = 0.28,P< 0.01). CL rates were faster in young patients and in those with low-VWF:Ag levels. CL rates of FVIII are higher in blood Group O versus non-blood Group O persons (5.02 ± 0.38 vs. 4.00 ± 0.32 ml·kg?1·h?1,t= 2.53,P= 0.02).Conclusions: Chinese boys with severe HA have similar PK values to other ethnic groups and large differences in FVIII PK between individual patients. Age, blood group, and VWF:Ag levels are important determining factors for FVIII CL.
引用
收藏
页码:1780 / 1785
页数:6
相关论文
共 50 条
  • [41] Is clinical phenotype of severe hemophilia A dependent on factor VIII genotype?
    Van Dijk, K
    Van der Bom, G
    van Amstel, JKP
    Fischer, K
    Mauser-Bunschoten, EP
    Nieuwenhuis, HK
    Zewald, RA
    Van den Berg, M
    BLOOD, 2003, 102 (11) : 801A - 801A
  • [42] Mutation analysis of factor VIII in Korean patients with severe hemophilia A
    Chur-Woo You
    Hee-Sook Son
    Hee Jin Kim
    Eui-Jeon Woo
    Soon-Ae Kim
    Haing-Woon Baik
    International Journal of Hematology, 2010, 91 : 784 - 791
  • [43] Mutation analysis of factor VIII in Korean patients with severe hemophilia A
    You, Chur-Woo
    Son, Hee-Sook
    Kim, Hee Jin
    Woo, Eui-Jeon
    Kim, Soon-Ae
    Baik, Haing-Woon
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2010, 91 (05) : 784 - 791
  • [44] Intensity of factor VIII treatment and inhibitor development in children with severe hemophilia A: the RODIN study
    Gouw, Samantha C.
    van den Berg, H. Marijke
    Fischer, Kathelijn
    Auerswald, Guenter
    Carcao, Manuel
    Chalmers, Elizabeth
    Chambost, Herve
    Kurnik, Karin
    Liesner, Ri
    Petrini, Pia
    Platokouki, Helen
    Altisent, Carmen
    Oldenburg, Johannes
    Nolan, Beatrice
    Perez Garrido, Rosario
    Mancuso, M. Elisa
    Rafowicz, Anne
    Williams, Mike
    Clausen, Niels
    Middelburg, Rutger A.
    Ljung, Rolf
    van der Bom, Johanna G.
    BLOOD, 2013, 121 (20) : 4046 - 4055
  • [45] Phase 3 study of recombinant factor VIII Fc fusion protein in severe hemophilia A
    Mahlangu, Johnny
    Powell, Jerry S.
    Ragni, Margaret V.
    Chowdary, Pratima
    Josephson, Neil C.
    Pabinger, Ingrid
    Hanabusa, Hideji
    Gupta, Naresh
    Kulkarni, Roshni
    Fogarty, Patrick
    Perry, David
    Shapiro, Amy
    Pasi, K. John
    Apte, Shashikant
    Nestorov, Ivan
    Jiang, Haiyan
    Li, Shuanglian
    Neelakantan, Srividya
    Cristiano, Lynda M.
    Goyal, Jaya
    Sommer, Jurg M.
    Dumont, Jennifer A.
    Dodd, Nigel
    Nugent, Karen
    Vigliani, Gloria
    Luk, Alvin
    Brennan, Aoife
    Pierce, Glenn F.
    BLOOD, 2014, 123 (03) : 317 - 325
  • [46] A single-center study of patients with rare isolated acquired clotting factor deficiencies other than acquired hemophilia A
    Yu, Dandan
    Xue, Feng
    Liu, Xiaofan
    Chen, Yunfei
    Fu, Rongfeng
    Sun, Ting
    Dai, Xinyue
    Ju, Mankai
    Dong, Huan
    Yang, Renchi
    Liu, Wei
    Zhang, Lei
    RESEARCH AND PRACTICE IN THROMBOSIS AND HAEMOSTASIS, 2024, 8 (06)
  • [47] Reduced-intensity, risk factor-stratified immunosuppression for acquired hemophilia A: single-center observational study
    Dobbelstein, Christiane
    Moschovakis, Georgios Leandros
    Tiede, Andreas
    ANNALS OF HEMATOLOGY, 2020, 99 (09) : 2105 - 2112
  • [48] A CASE OF FACTOR-VIII AG-POSITIVE SEVERE HEMOPHILIA A WITH FACTOR-VIII INHIBITOR
    SHIMA, M
    IMAI, S
    TSUBURA, Y
    YOSHIOKA, A
    FUJIMURA, Y
    SUGIMOTO, M
    FUKUI, H
    THROMBOSIS AND HAEMOSTASIS, 1985, 54 (01) : 78 - 78
  • [49] An Open-label, Single-dose, Pharmacokinetic Study of Factor VIII Activity After Administration of Moroctocog Alfa (AF-CC) in Male Chinese Patients With Hemophilia A
    Liu, Hongzhong
    Wu, Runhui
    Hu, Pei
    Sun, Feifei
    Xu, Lihong
    Liang, Yali
    Nepal, Sunil
    Qu, Peng Roger
    Huard, Francois
    Korth-Bradley, Joan M.
    CLINICAL THERAPEUTICS, 2017, 39 (07) : 1313 - 1319
  • [50] Population Pharmacokinetic Model of Recombinant Single-Chain Factor VIII (rVIII-Singlechain) in Patients with Hemophilia A
    Zhang, Y.
    Roberts, J.
    Bensen-Kennedy, D.
    Veldman, A.
    Sidhu, J.
    HAEMOPHILIA, 2016, 22 : 103 - 103